Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ripretinib (DCC-2618) is an orally bioavailable inhibitor of KIT and PDGFRA.
説明 | Ripretinib (DCC-2618) is an orally bioavailable inhibitor of KIT and PDGFRA. |
別名 | DCC-2618 |
分子量 | 510.36 |
分子式 | C24H21BrFN5O2 |
CAS No. | 1442472-39-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 40 mg/mL(78.38 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ripretinib 1442472-39-0 Angiogenesis Apoptosis Tyrosine Kinase/Adaptors FLT VEGFR c-Kit PDGFR Inhibitor Vascular endothelial growth factor receptor CD135 CD117 DCC-2618 Platelet-derived growth factor receptor inhibit Cluster of differentiation antigen 135 SCFR Fms like tyrosine kinase 3 FLT3 DCC2618 DCC 2618 inhibitor